Zentalis Pharmaceuticals, Inc. Annual Report: A Simple Guide

I’m writing this guide to help you understand how Zentalis Pharmaceuticals performed this year. My goal is to turn complex filing information into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Zentalis is a clinical-stage biotech company. They are still in the research lab phase and do not sell finished medicines yet. Their success depends on their lead drug candidate, azenosertib (ZN-c3). This drug targets cancer cells with high levels of a protein called Cyclin E1. This year, the company focused on proving the drug works for patients with platinum-resistant ovarian cancer, a condition with few treatment options.

2. Financial health and cash usage

Because they have no product on the market, the company is not profitable. For the year ending December 31, 2024, they reported a loss of about $311.5 million.

As of year-end, they held $252.8 million in cash and investments. Since they spend over $250 million annually, they only have enough money to operate into the second half of 2025. To stay afloat, they have sold more shares, which reduces your ownership percentage. They will need to raise more money to reach their next trial results.

3. Major shifts and strategy

In early 2025, the company restructured to cut costs and focus entirely on azenosertib. They reduced their workforce and stopped working on earlier-stage projects to save cash.

They are now focusing on patients with the "Cyclin E1" biological signature. By targeting these specific patients, they hope to see better results in their trials. They also regained full rights to azenosertib from previous partners, meaning they keep 100% of the potential profits if the drug succeeds.

4. What’s next?

The company’s future depends on two major clinical trials:

• DENALI: This is a critical Phase 2 study. They finished enrolling patients and expect results by the end of 2026. If the drug works well, they will ask the FDA for accelerated approval.
• ASPENOVA: This is a larger Phase 2/3 study. It is designed to confirm the drug’s effectiveness for full regulatory approval.

They are also developing a test to identify which patients have the right biological signature to benefit from the drug. The FDA will likely require this test to be approved alongside the medicine.

5. Key risks

The company’s business is "all-or-nothing."

• Clinical Failure: If the DENALI trial fails, the company has no other late-stage products. This would likely cause the share price to drop significantly.
• Cash Crunch: They need more money by late 2025. If they cannot raise funds or find a partner, they may have to stop trials or face bankruptcy.
• Competition: Many large pharmaceutical companies are developing rival treatments. If a competitor creates a better or safer drug, Zentalis’s opportunity will shrink.
• Regulatory Risk: The FDA has strict rules for approval. Even with good data, they may demand more time-consuming trials.

Final Thought for Investors: Zentalis is a high-risk, high-reward bet. You are essentially investing in the outcome of the DENALI and ASPENOVA trials. Because the company is burning through cash quickly and has no other products to fall back on, the primary question to ask yourself is whether you believe the clinical data will be strong enough to secure FDA approval before the company runs out of money.